Subpopulations of myeloid‐derived suppressor cells impair T cell responses through independent nitric oxide‐related pathways

No abstract is available for this paper.

• Publication year

  2014

• Venue

  International Journal of Cancer

• Publication date

  2014-06-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ijc.28622PMID 24259296PMCID PMC3980009
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Abstract 1515: Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer.

  2013cited by this paper
• Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?

  2013cited by this paper
• Tumor-Expressed Inducible Nitric Oxide Synthase Controls Induction of Functional Myeloid-Derived Suppressor Cells through Modulation of Vascular Endothelial Growth Factor Release

  2012cited by this paper
• Coordinated regulation of myeloid cells by tumours

  2012cited by this paper
• Metabolism of L-Arginine by Myeloid-Derived Suppressor Cells in Cancer: Mechanisms of T cell suppression and Therapeutic Perspectives

  2012cited by this paper
• Regulation by S-Nitrosylation of Protein Post-translational Modification*

  2011cited by this paper
• Myeloid derived suppressor cells in human diseases.

  2011cited by this paper
• Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice.

  2011cited by this paper
• Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells

  2011cited by this paper
• eNOS activation and NO function: structural motifs responsible for the posttranslational control of endothelial nitric oxide synthase activity.

  2011cited by this paper
• A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells.

  2011cited by this paper
• Modulation of human T‐cell functions by reactive nitrogen species

  2011cited by this paper
• Metabolomic screening and identification of the bioactivation pathways of ritonavir.

  2011cited by this paper
• Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine.

  2010cited by this paper
• Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor.

  2010cited by this paper
• CD49d Is a New Marker for Distinct Myeloid-Derived Suppressor Cell Subpopulations in Mice

  2010cited by this paper
• Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13.

  2010cited by this paper
• Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes.

  2009cited by this paper
• Mechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor Cells1

  2009cited by this paper
• Induced nitric oxide synthase as a major player in the oncogenic transformation of inflamed tissue.

  2009cited by this paper
• Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-1(27-35)-reactive T cells from activation-induced cell death.

  2009cited by this paper
• Myeloid-derived suppressor cells as regulators of the immune system

  2009cited by this paper
• Pure MnTBAP selectively scavenges peroxynitrite over superoxide: comparison of pure and commercial MnTBAP samples to MnTE-2-PyP in two models of oxidative stress injury, an SOD-specific Escherichia coli model and carrageenan-induced pleurisy.

  2009cited by this paper
• Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice1

  2008cited by this paper
• Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives

  2008cited by this paper
• Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity.

  2008cited by this paper
• The terminology issue for myeloid-derived suppressor cells.

  2007influential reference
• Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer

  2007cited by this paper
• Cross-Talk between Myeloid-Derived Suppressor Cells and Macrophages Subverts Tumor Immunity toward a Type 2 Response1

  2007cited by this paper
• Mycobacteria‐induced Gr‐1+ subsets from distinct myeloid lineages have opposite effects on T cell expansion

  2007cited by this paper
• Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression.

  2007cited by this paper
• Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells.

  2006cited by this paper
• Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer.

  2006influential reference
• Peroxisome proliferator-activated receptor γ (PPARγ) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer

  2006cited by this paper
• Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion.

  2005cited by this paper
• Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination.

  2005cited by this paper
• Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma

  2005cited by this paper
• STAT1 Signaling Regulates Tumor-Associated Macrophage-Mediated T Cell Deletion1

  2005influential reference
• Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers

  2005cited by this paper
• Reduction of Myeloid-Derived Suppressor Cells and Induction of M1 Macrophages Facilitate the Rejection of Established Metastatic Disease1

  2005influential reference
• Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis.

  2005cited by this paper
• Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses

  2004influential reference
• Antigen-Specific Inhibition of CD8+ T Cell Response by Immature Myeloid Cells in Cancer Is Mediated by Reactive Oxygen Species1

  2004cited by this paper
• Reactions of PTIO and carboxy-PTIO with *NO, *NO2, and O2-*.

  2003cited by this paper
• Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells.

  2000cited by this paper
• Peroxynitrite inhibits T lymphocyte activation and proliferation by promoting impairment of tyrosine phosphorylation and peroxynitrite-driven apoptotic death.

  1999cited by this paper

• Tumor microenvironment dynamics in gastric cancer pathogenesis and therapeutic resistance

  2026cites this paper
• Gasotransmitters bridging tumor biology and immunity: from pathophysiological insights to therapeutic potential

  2026cites this paper
• Engineering T Cells with Membrane-Anchored Nitric Oxide Scavengers for Anticancer Therapy.

  2026cites this paper
• Mac-1 regulates disease stage–specific immunosuppression via the nitric oxide pathway in autoimmune disease

  2025cites this paper
• Immunosuppressive cells in acute myeloid leukemia: mechanisms and therapeutic target

  2025cites this paper
• The characteristics of the tumor immune microenvironment in colorectal cancer with different MSI status and current therapeutic strategies

  2025cites this paper
• Recent advances in regulatory immune cells: exploring the world beyond Tregs

  2025cites this paper
• Crosstalk between cancer stem cells and myeloid-derived suppressor cells: implications for tumor progression and immunotherapy

  2025cites this paper
• Therapeutic Advances in Metastatic Prostate Cancer: A Journey from Standard of Care to New Emerging Treatment

  2025cites this paper
• Recruitment of Polymorphonuclear Myeloid-Derived Suppressor Cells During Cryptococcus neoformans Infection.

  2025cites this paper
• Immunomodulation of the Breast Cancer Microenvironment by Tumor-Derived Exosomes: Implications for Immunotherapy

  2025cites this paper
• Reprogramming the immune microenvironment in lung cancer

  2025cites this paper
• Nitric oxide-modulating biomaterials for therapeutic Immunoengineering.

  2025cites this paper
• Spatial heterogeneity in glioblastoma: Decoding the role of perfusion.

  2025cites this paper
• Glucocorticoid Receptor-Targeted Nanoliposome for STAT3 Inhibition-Led Myeloid-Derived Suppressor Cell Modulation and Efficient Colon Cancer Treatment.

  2025cites this paper
• Myeloid-derived suppressor cells modulation in the context of tumor microenvironment for gastric cancer

  2025cites this paper
• Targeting myeloid cells to improve cancer immune therapy

  2025cites this paper
• Targeting myeloid cell immunometabolism to improve current non-small cell lung cancer therapies.

  2025cites this paper
• Myeloid cells are involved in tumor immunity, metastasis and metabolism in tumor microenvironment

  2025cites this paper
• Mechanisms of immunotherapy in cutaneous squamous cell carcinoma in the tumor microenvironment

  2025cites this paper
• IFNβ−pSTAT1-IRF1 axis controls colorectal tumor development through induction of immunogenic Ly6C+myeloid cells

  2025cites this paper
• Endoplasmic Reticulum Stress in Cancer

  2025cites this paper
• Transforming cancer immunotherapy: Overcoming immunosuppression in tumors via gene silencing techniques based on nanoparticles

  2025cites this paper
• Anti-HER2/Neu Antibody Therapy Inhibits HER2+ Breast Cancer by Blocking Myeloid-Derived Suppressor Cell Activity.

  2025cites this paper
• HLA molecules: Another challenge for CAR T cell therapy.

  2025cites this paper
• Potential Biomarkers of Therapeutic Response to ECP in Solid Organ Transplantation

  2025cites this paper
• Targeted nanomedicine for reprogramming the tumor innate immune system: From bench to bedside.

  2024cites this paper
• Biochemistry, pharmacology, and in vivo function of arginases

  2024cites this paper
• Mediating role of circulating inflammatory proteins in the effect of immune cells on esophageal cancer risk: A Mendelian randomization study

  2024cites this paper
• Emergency myelopoiesis in solid cancers

  2024cites this paper
• Therapeutic advantage of combinatorial CAR T cell and chemo-therapies.

  2024cites this paper
• Modulation of macrophage metabolism as an emerging immunotherapy strategy for cancer

  2024cites this paper
• WNT2 blockade augments antitumor immunity by attenuating myeloid‐derived suppressor cells in colorectal cancer

  2024cites this paper
• Loss of LECT2 promotes ovarian cancer progression by inducing cancer invasiveness and facilitating an immunosuppressive environment

  2024cites this paper
• Advances in CAR-T therapy for central nervous system tumors

  2024cites this paper
• 粒细胞样髓源性抑制细胞在非小细胞肺癌中的研究进展

  2024cites this paper
• γ-aminobutyric acid receptor B signaling drives glioblastoma in females in an immune-dependent manner

  2024cites this paper
• Tumor microenvironment as niche constructed by cancer stem cells: Breaking the ecosystem to combat cancer

  2024cites this paper
• Myeloid-derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in colorectal cancer (Review)

  2024cites this paper
• Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives

  2024cites this paper
• Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion

  2024cites this paper
• Treatment strategies and molecular mechanism of radiotherapy combined with immunotherapy in colorectal cancer.

  2024cites this paper
• Photodynamic Therapy and Adaptive Immunity Induced by Reactive Oxygen Species: Recent Reports

  2024influential citation
• Targeting the breast tumor microenvironment by plant-derived products and their nanoformulations

  2024cites this paper
• Mechanisms underlying immunosuppression by regulatory cells

  2024cites this paper
• Current state of immune checkpoints therapy for glioblastoma

  2024cites this paper
• Estimating nitric oxide (NO) from MDSCs by Griess method.

  2024cites this paper
• Neutrophils' dual role in cancer: from tumor progression to immunotherapeutic potential.

  2024cites this paper
• Increased circulating polymorphonuclear myeloid-derived suppressor cells are associated with prognosis of metastatic castration-resistant prostate cancer

  2024cites this paper
• The role of tumor-associated macrophages in tumor immune evasion

  2024cites this paper
• The Anti-Tumorigenic Role of Cannabinoid Receptor 2 in Colon Cancer: A Study in Mice and Humans

  2023cites this paper
• High-Throughput Screening and Proteomic Characterization of Compounds Targeting Myeloid-Derived Suppressor Cells

  2023cites this paper
• Tumor metabolic crosstalk and immunotherapy

  2023cites this paper
• Cancer micro-environment immune modulation by Egyptian cobra (Naja haje) crud venom

  2023cites this paper
• Mononuclear myeloid-derived suppressor cells expansion is associated with progression of liver failure in patients with acute decompensation of cirrhosis.

  2023cites this paper
• The Use of Targeted Cytokines as Cancer Therapeutics in Glioblastoma

  2023cites this paper
• Fully functional monocytic MDSC generation from the murine HoxB8 cell line

  2023cites this paper
• Cellular and Molecular Players in the Tumor Microenvironment of Renal Cell Carcinoma

  2023cites this paper
• The Triple Crown: NO, CO, and H2S in cancer cell biology.

  2023cites this paper
• Halofuginone ameliorates systemic lupus erythematosus by targeting Blk in myeloid-derived suppressor cells.

  2023cites this paper
• Metabolic reprogramming of myeloid-derived suppressor cells in the context of organ transplantation.

  2023cites this paper
• Interdependencies of the Neuronal, Immune and Tumor Microenvironment in Gliomas

  2023cites this paper
• Autoimmunity and Carcinogenesis: Their Relationship under the Umbrella of Autophagy

  2023cites this paper
• CD11b+Gr-1low cells that accumulate in M.leprae-induced granulomas of the footpad skin of nude mice have the characteristics of monocytic-myeloid-derived suppressor cells.

  2023cites this paper
• Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond

  2023cites this paper
• Deciphering the roles of myeloid derived suppressor cells in viral oncogenesis

  2023cites this paper
• Interaction of gut microbiota with the tumor microenvironment: A new strategy for antitumor treatment and traditional Chinese medicine in colorectal cancer

  2023cites this paper
• Immunosuppression by Inflammation-Stimulated Amplification of Myeloid-Derived Suppressor Cells and Changes in Expression of Immune Checkpoint HHLA2 in Chronic Obstructive Pulmonary Disease

  2023cites this paper
• Role of myeloid-derived suppressor cells during Trypanosoma cruzi infection.

  2023cites this paper
• Fluorescent Detection of Peroxynitrite Produced by Myeloid-Derived Suppressor Cells in Cancer and Inhibition by Dasatinib.

  2023cites this paper
• Myeloidcells in the immunosuppressive microenvironment in glioblastoma: The characteristics and therapeutic strategies

  2023cites this paper
• Lnc-17Rik promotes the immunosuppressive function of Myeloid-Derived suppressive cells in esophageal cancer.

  2023cites this paper
• The immune suppressive tumor microenvironment in multiple myeloma: The contribution of myeloid-derived suppressor cells

  2023cites this paper
• Tumor microenvironment promotes lymphatic metastasis of cervical cancer: its mechanisms and clinical implications

  2023cites this paper
• Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patients

  2023cites this paper
• Progress in research on the role played by myeloid‐derived suppressor cells in liver diseases

  2023cites this paper
• STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice

  2022cites this paper
• Expression of Hv1 proton channels in myeloid-derived suppressor cells (MDSC) and its potential role in T cell regulation

  2022cites this paper
• Autoimmunity and Cancer—Two Sides of the Same Coin

  2022cites this paper
• Friends with Benefits: Chemokines, Glioblastoma-Associated Microglia/Macrophages, and Tumor Microenvironment

  2022cites this paper
• Recent Advances in Cell Therapeutics for Systemic Autoimmune Diseases

  2022cites this paper
• Immunotherapy for glioblastoma: the promise of combination strategies

  2022cites this paper
• The Role of Myeloid-Derived Suppressor Cells in Tumor Growth and Metastasis.

  2022cites this paper
• Granulocyte-Macrophage Colony-Stimulating Factor Modulates Myeloid-Derived Suppressor Cells and Treg Activity in Decompensated Cirrhotic Patients With Sepsis

  2022cites this paper
• Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma

  2022cites this paper
• Neutrophil‐T cell crosstalk and the control of the host inflammatory response

  2022cites this paper
• Advances in Nanotechnology for Cancer Immunoprevention and Immunotherapy: A Review

  2022cites this paper
• Role of myeloid-derived suppressor cells in the formation of pre-metastatic niche

  2022cites this paper
• Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy

  2022cites this paper
• New Perspectives on Myeloid-Derived Suppressor Cells and Their Emerging Role in Haematology

  2022cites this paper
• Tumor Environment Promotes Lnc57Rik-Mediated Suppressive Function of Myeloid-Derived Suppressor Cells

  2022cites this paper
• Pharmacological modulation of myeloid-derived suppressor cells to dampen inflammation

  2022influential citation
• Myeloid-derived suppressor cells and vaccination against pathogens

  2022influential citation
• Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy

  2022cites this paper
• Myeloid-Derived Suppressor Cells: New Insights into the Pathogenesis and Therapy of MDS

  2022cites this paper
• Emerging roles for IL-25 and IL-33 in colorectal cancer tumorigenesis

  2022cites this paper
• Long Noncoding RNA MIR4435-2HG Suppresses Colorectal Cancer Initiation and Progression By Reprogramming Neutrophils

  2022cites this paper
• Granulocytic myeloid-derived suppressor cells to prevent and treat murine immune-mediated bone marrow failure

  2022cites this paper
• Emerging immune-based technologies for high-grade gliomas

  2022cites this paper
• Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin

  2022cites this paper